Compare Stocks → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRDLNASDAQ:CRTXNASDAQ:HARPNASDAQ:RUBY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$2.21+10.5%$1.77$0.55▼$2.22$150.90M0.87360,815 shs887,944 shsCRTXCortexyme$0.92+1.1%$1.11$1.78▼$40.66$27.74M1.4620,672 shs41,972 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/ARUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics+10.50%+11.62%+15.10%+108.49%+268.33%CRTXCortexyme0.00%-5.21%-12.50%-30.00%-47.09%HARPHarpoon Therapeutics0.00%0.00%0.00%+2.49%+189.14%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%+179.41%The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics2.6093 of 5 stars3.55.00.00.03.80.00.0CRTXCortexymeN/AN/AN/AN/AN/AN/AN/AN/AHARPHarpoon Therapeutics1.212 of 5 stars2.20.00.04.70.04.20.0RUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics3.00Buy$6.00171.49% UpsideCRTXCortexymeN/AN/AN/AN/AHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsideRUBYRubius TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest RUBY, HARP, CRDL, and CRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.003/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform2/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol Therapeutics$60K2,514.98N/AN/A$0.32 per share6.91CRTXCortexymeN/AN/AN/AN/A$3.97 per shareN/AHARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$20.84M-$0.33N/AN/AN/AN/A-76.18%-62.52%5/20/2024 (Estimated)CRTXCortexyme-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/AHARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ALatest RUBY, HARP, CRDL, and CRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023CRDLCardiol TherapeuticsN/A-$0.09-$0.09-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/ACRTXCortexymeN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.014.364.36CRTXCortexymeN/A9.929.92HARPHarpoon TherapeuticsN/A1.891.89RUBYRubius TherapeuticsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%CRTXCortexyme63.18%HARPHarpoon Therapeutics74.01%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%CRTXCortexyme27.90%HARPHarpoon Therapeutics17.00%RUBYRubius Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol TherapeuticsN/A68.28 million64.70 millionNot OptionableCRTXCortexyme5530.15 million21.74 millionNot OptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableRUBY, HARP, CRDL, and CRTX HeadlinesSourceHeadline‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)yahoo.com - April 26 at 3:33 AMVacant Rubius property generating interest after 1 year on marketpbn.com - April 18 at 1:01 AMSensorium Therapeutics Appoints Sam Rasty as Chief Business Officercitizentribune.com - April 17 at 8:01 PMVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'bizjournals.com - March 11 at 5:07 PMRubius Therapeutics Inc RUBYmorningstar.com - November 5 at 8:39 PM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorbostonglobe.com - October 16 at 7:58 AMRuby Dunne Biography & Moviestribute.ca - September 22 at 6:08 PMParenting Vlogger Ruby Franke Held Without Bail on Child Abuse Chargesoxygen.com - September 14 at 8:44 PMYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowtoday.com - September 8 at 6:33 PMRuby Gonzalesdailynews.com - August 21 at 8:30 AMRUBY - Rubius Therapeutics, Inc.uk.finance.yahoo.com - August 2 at 2:37 AMNorth American Morning Briefing: Alphabet, -2-morningstar.com - July 25 at 7:07 AMRuby Rivera, 23ABCturnto23.com - July 1 at 12:54 AMRuby Speakingcomedy.co.uk - June 23 at 3:11 PMRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternativesfinance.yahoo.com - March 2 at 1:59 AMWhatever happened to Ruby?infoworld.com - February 17 at 4:07 PMThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?marketwatch.com - February 14 at 7:55 PMWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?msn.com - February 14 at 9:54 AMThe Wrap: Ruby's moving to Congress Street, launching new French conceptyahoo.com - January 25 at 4:27 AMRuby Wax sparks concern from fans after posting video from hospital bedmirror.co.uk - January 12 at 12:51 AMRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookdailymail.co.uk - January 12 at 12:51 AMFormer Rubius CEO jumps to another Flagship spinoutfinance.yahoo.com - November 18 at 10:30 AMRubius Therapeutics lays off most of its staff, explores salefinance.yahoo.com - November 4 at 12:16 PMRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternativesfinance.yahoo.com - November 3 at 1:47 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks GE Aerospace is Ready for Liftoff After Strong EarningsApril 24, 2024 9:07 AMView GE Aerospace is Ready for Liftoff After Strong EarningsTraders Sell but Investors Still Win After Palantir's EarningsMay 7, 2024 9:16 AMView Traders Sell but Investors Still Win After Palantir's EarningsRoku Trims Losses and Raises Guidance, But Market Isn’t ConvincedApril 29, 2024 6:15 AMView Roku Trims Losses and Raises Guidance, But Market Isn’t ConvincedAll Headlines Company DescriptionsCardiol TherapeuticsNASDAQ:CRDLCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.CortexymeNASDAQ:CRTXCortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.Rubius TherapeuticsNASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.